In short, based on the continuous discovery of CAFs subtypes in TME, reducing the tumor-promoting CAFs subsets in TME and increasing the tumor-inhibiting CAFs subsets can make the targeted CAFs treatment of tumors more accurate. The gene discussed is TBX1; the disease is neoplasm.